FLUVOXAMINE

18. DeBree H, Van der Schoot JB & Post LC: Fluvoxamine maleate; disposition in man. Eur J Drug Metab Pharmacokinet 1983; 8:175-179.
19. DeJong GJ: The use of pre-column for the direct high-performance liquid chromatographic determination of the antidepressants clovoxamine and fluvoxamine in plasma. J Chromatog 1980; 183:203-211.
20. Demisch K, Demisch L, Bochnik HJ et al: Melatonin and cortisol increase after fluvoxamine. Br J Clin Pharmacol 1986; 22:620-622.
21. DeWilde JE, Mertens C & Wakelin JS: Clinical trials of fluvoxamine vs chlorimipramine with single and three times daily dosing. Br J Clin Pharmacol 1983; 15:427S-431S.
22. DeWilde JEM & Doogan DP: Fluvoxamine and chlorimipramine in endogenous depression. J Affective Disord 1982; 4:249-259.
23. Dick P & Ferrero E: A double-blind comparative study of the clinical efficacy of fluvoxamine and chlorimipramine. Br J Clin Pharmacol 1983; 15:419S-425S.
24. Doogan DP: Fluvoxamine as an antidepressant drug. Neuropharmacology 1980; 19:1215-1216.
25. Dursun SM, Burke JG, Nielsen F et al: SSRI-related toxic serotonin syndrome: improvement of discontinuation of treatment and propranolol. Eur Psychiatr 1997; 12:321-323.
26. FDA: Poison treatment drug product for over-the-counter human use; tentative final monograph. Fed Register 1985; 50:2244-2262.
27. Feldmann HS & Denber HCB: Long-term study of fluvoxamine: a new rapid-acting antidepressant. Intl Pharmacopsychiatry 1982; 17:114-122.
28. Gallerani M, Grassi L, Ferrari F et al: Electrocardiographic alterations as a result of acute intoxication with fluvoxamine and pipamperone. Clin Drug Invest 1998; 15:64-68.
29. Garnier R, Azoyan P, Chataigner D et al: Acute fluvoxamine poisoning. Int Med Res 1993; 21:197-208.
30. Giang DW & McBride MC: Lorazepam versus diazepam for the treatment of status elipticus. Pediatr Neurol 1988; 4:358-361.
31. Gillman PK: Ecstasy, serotonin syndrome and the treatment of hyperpyrexia (letter). MJA 1997; 167:109-111.
32. Goldberg RJ & Huk M: Serotonin syndrome from trazodone and buspirone (letter). Psychosomatics 1992; 33:235-236.
33. Goodman WK, Price LH & Charney DS: Fluvoxamine in obsessive compulsive disorder. Psychiatric Annals 1989; 19:92-96.
34. Graham PM: Successful treatment of the toxic serotonin syndrome with chlorpromazine (letter). Med J Australia 1997; 166:166-167.
35. Green BH: Br J Paychiatr 1988; 153:130-131.
36. Guelfi JD, Dreyfus JF, Pichot P et al: A double-blind controlled clinical trial comparing fluvoxamine with imipramine. Br J Clin Pharmacol 1983; 15:411S-417S.
37. Guy W, Wilson WH, Ban TA et al: A double-blind clinical trial of fluvoxamine and imipramine in patients with primary depression. Psychopharmacol Bull 1984; 20:73-78.
38. Guze BH & Baxter LR Jr: The serotonin syndrome: case responsive to propranolol (letter). J Clin Psychopharmacol 1986; 6:119-120.
39. Hoes MJAJM: Mirtazapine as treatment for serotonin syndrome. Pharmacopsychiatry 1996; 29:81.
40. Hurst HE, Jones DR, Jarboe CH et al: Determination of clovoxamine concentration in human plasma by electron capture gas chromatograpy. Clin Chem 1981; 27:1210-1212.
41. Kline SS, Mauro LS, Scala-Barnett DM et al: Serotonin syndrome versus neuroleptic malignant syndrome as a cause of death. Clin Pharmac 1989; 8:510-514.
42. Lahat E, Goldman M, Barr J et al: Comparison of intranasal midazolam with intravenous diazepam for treating febrile seizures in children: prospective randomized study. BMJ 2000; 321:83-86.
43. Lam KS, Blanchi A, Chavaillon JM: Hepatite probablement secondaire a la prise massive de fluvoxamine. Gastroenterol Clin Biol 1988; 12:398-399.
44. Langlois RP & Paqueete D: Sustained bradycardia during fluvoxamine and buspirone intoxication. Canad J Psychiat 1994; 39:126-127.
45. Lapierre YD, Rastogi RB & Singhal RL: Fluvoxamine influences serotonergic system in the brain: neurochemical evidence. Neuropsychobioloby 1983; 10:213-216.
46. Martin AJ, Tebbs VM & Ashford JJ: Affective disorders in general practice. Treatment of 6000 patients with fluvoxamine. Pharmatherapeutica 1987; 5:40-49.
47. Mills KC: Serotonin syndrome: a clinical update. Med Toxicol 1997; 13:763-783.
48. Overmars H, Scherpenisse PM & Post LC: Fluvoxamine maleate: metabolism in man. Eur J Drug Metabol Pharmacokinet 1983; 8:269-280.
49. Price LH, Goodman WK, Charney DS et al: Treatment of severe obsessive-compulsive disorder with fluvoxamine. Am J Psychiatry 1987; 144:1059-1061.
50. Product Information Ativan(R), 1999, Wyeth-Ayerst Co, Philadelphia, PA
51. Product Information: Ativan(R), lorazepam. Wyeth, Philadelphia, PA, 1991.
52. Reynolds JEF (Ed): Martindale: The extra Pharmacopoeia (electronic version). Micromedex, Inc, Denver, CO, 1990.
53. Richelson E & Nelson A: Antagonism by antidepressants of neurotransmitter receptors of normal human brain in vitro. J Pharmacol Exp Therap 1984; 230:94-102.
54. Robinson JF & Doogan DP: A placebo controlled study of the cardiovascular effects of fluvoxamine and clovoxamine in human volunteers. Br J Clin Pharmacol 1982; 14:805-808.
55. Roos JC: Cardiac effects of antidepressant drugs: a comparison of the tricyclic antidepressants and fluvoxamine. Br J Clin Pharmacol 1983; 15(suppl 3):439S-445S.
56. Saletu B, Schjerve M, Grunberger J et al: Fluvoxamine- a new serotonin re-uptake inhibitor: first clinical and psychometric experiences in depressed patients. J Neural Transm 1977; 41:17-36.
57. Scott R, Besag FMC, Neville BGR: Buccal midazolam and rectal diazepam for treatment of prolonged seizures in childhood and adolescence: a randomized trial. Lancet 1999; 353:623-626.
58. Siddiqui UA, Chakravarti SK & Jesinger DK: The tolerance and antidepressive activity of fluvoxamine as a single dose compared to a twice daily dose. Curr Med Res Op 1985; 9:681-690.
59. Sternbach H: The serotonin syndrome. Am J Psychiatr 1992; 149:1410-1411.
60. USP DI Volume I Drug information for the health care professional. 20th edition, 2000; Micromedex Inc, World Color Book Services, Taunton, MA.
61. Vale JA: Position Statement: gastric lavage. American Academy of Clinical Toxicology/European Association of Poisons Centres and Clinical Toxicologists. Clin Toxicol 1997; 35:711-719.
62. Wheeler SC, Vlasses PH, Dobinska MR et al: Plasma fluvoxamine levels in fasted and fed subjects. J Clin Pharmacol 1985; 25:463.
63. Wilson WH, Higano H, Papdatos Y et al: A double-blind placebo-controlled study to compare the autonomic effects of fluvoxamine with those of amitriptyline and doxepin in healthy volunteers. Br J Clin Pharmacol 1983; 15:385S-392S.
64. Wouthers W & Deiman W: Acute cardiac effects of fluvoxamine and other antidepressants in conscious rabbits. Arch Int Pharmacodyn 1983; 263:197-207.
65. Wright JH & Denber HCB: Clinical trial of fluvoxamine: a new serotonergic antidepressant. Clin Ther Res 1978; 23:83-89.

13.0 AUTHOR INFORMATION

13.1 CONTRIBUTOR(S) TO THIS DOCUMENT

A. Original publication: 07/90
B. Most recent revision: 03/98

§ C. List of contributors:

§ 1. Steve Silverstein, MD

§ 2. POISINDEX(R) Editorial Staff

D. Specialty Board: CNS DRUGS

Refer to the POISINDEX EDITORIAL BOARD section for more information. (MG0778)

End of Document